The Association of the Oxford Classification Score with Longitudinal Estimated Glomerular Filtration Rate Decline in Patients with Immunoglobulin A Nephropathy: A Mixed-Method Study

References

• Hou JH, Zhu HX, Zhou ML, et al. Changes in the Spectrum of Kidney Diseases: an Analysis of 40,759 Biopsy-Proven Cases from 2003 to 2014 in China. Kidney Dis. 2018;4(1):10–19. doi:10.1159/000484717
   Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414. doi:10.1056/NEJMra1206793
   PubMed Web of Science ®Google Scholar
• D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–237. doi:10.1053/ajkd.2000.8966
   PubMed Web of Science ®Google Scholar
• Roufosse CA, Cook HT. Pathological predictors of prognosis in immunoglobulin A nephropathy: a review. Curr Opin Nephrol Hypertens. 2009;18(3):212–219. doi:10.1097/MNH.0b013e328329605c
   PubMed Web of Science ®Google Scholar
• Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503–512.
   PubMed Web of Science ®Google Scholar
• Manno C, Strippoli GF, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49(6):763–775. doi:10.1053/j.ajkd.2007.03.013
   PubMed Web of Science ®Google Scholar
• Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant. 2005;20(2):342–348. doi:10.1093/ndt/gfh633
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–545. doi:10.1038/ki.2009.243
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–1021. doi:10.1016/j.kint.2017.02.003
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, et al. VALIGA study of the ERA-EDTA Immunonephrology Working Group: validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–836. doi:10.1038/ki.2014.63
   PubMed Web of Science ®Google Scholar
• Markowitz G. Glomerular disease: updated Oxford Classification of IgA nephropathy: a new MEST-C score. Nat Rev Nephrol. 2017;13(7):385–386. doi:10.1038/nrneph.2017.67
   PubMed Web of Science ®Google Scholar
• Yoon CY, Chang TI, Kang EW, et al. Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. Ann Med. 2017;49(3):217–229. doi:10.1080/07853890.2016.1252058
   PubMed Web of Science ®Google Scholar
• Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6(12):2806–2813. doi:10.2215/CJN.02890311
   PubMed Web of Science ®Google Scholar
• Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011;80(3):310–317. doi:10.1038/ki.2011.126
   PubMed Web of Science ®Google Scholar
• El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol. 2012;23(1):137–148. doi:10.1681/ASN.2010111130
   PubMed Web of Science ®Google Scholar
• Shi SF, Wang SX, Jiang L, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011;6(9):2175–2184. doi:10.2215/CJN.11521210
   PubMed Web of Science ®Google Scholar
• Shima Y, Nakanishi K, Hama T, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27(5):783–792. doi:10.1007/s00467-011-2061-0
   PubMed Web of Science ®Google Scholar
• Le W, Zeng CH, Liu Z, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol. 2012;13:158. doi:10.1186/1471-2369-13-158
   PubMed Web of Science ®Google Scholar
• Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60(5):812–820. doi:10.1053/j.ajkd.2012.06.011
   PubMed Web of Science ®Google Scholar
• Kang SH, Choi SR, Park HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012;27(1):252–258. doi:10.1093/ndt/gfr295
   PubMed Web of Science ®Google Scholar
• Espinosa M, Ortega R, Sánchez M, et al. Spanish Group for Study of Glomerular Diseases (GLOSEN): association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9(5):897–904. doi:10.2215/CJN.09710913
   PubMed Web of Science ®Google Scholar
• Park KS, Han SH, Kie JH, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. Hum Pathol. 2014;45(2):236–243. doi:10.1016/j.humpath.2013.08.019
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Camilla R; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77(10):921–927. doi:10.1038/ki.2010.43
   PubMed Web of Science ®Google Scholar
• Lee H, Yi SH, Seo MS, et al. Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults. Korean J Intern Med. 2012;27(3):293–300. doi:10.3904/kjim.2012.27.3.293
   PubMed Web of Science ®Google Scholar
• Shen XH, Liang SS, Chen HM, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28(4):441–449. doi:10.1007/s40620-014-0165-x
   PubMed Web of Science ®Google Scholar
• Haas M, Verhave JC, Liu ZH, et al. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol. 2017;28(2):691–701. doi:10.1681/ASN.2016040433
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Passafaro TL, Van de Stroet D, Bello NM, Williams NH, Rosa GJM. Generalized additive mixed model on the analysis of total transport losses of market-weight pigs1. J Anim Sci. 2019;97(5):2025–2034. doi:10.1093/jas/skz087
   PubMed Web of Science ®Google Scholar
• Coppo R, D’Arrigo G, Tripepi G, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant. 2020;35(6):1002–1009. doi:10.1093/ndt/gfy302
   PubMed Web of Science ®Google Scholar
• Yang P, Chen X, Zeng L, Hao H, Xu G. The response of the Oxford classification to steroid in IgA nephropathy: a systematic review and meta-analysis. Oncotarget. 2017;8(35):59748–59756. doi:10.18632/oncotarget.19574
   PubMedGoogle Scholar
• Beckwith H, Medjeral-Thomas N, Galliford J, et al. Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrol Dial Transplant. 2017;32(suppl_1):i123–i128. doi:10.1093/ndt/gfw326
   PubMed Web of Science ®Google Scholar
• Jullien P, Laurent B, Berthoux F, et al. Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant. 2020;35(7):1179–1186. doi:10.1093/ndt/gfy341
   PubMed Web of Science ®Google Scholar
• Roberts IS, Cook HT, Troyanov S; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–556. doi:10.1038/ki.2009.168
   PubMed Web of Science ®Google Scholar
• Coppo R, Troyanov S, Bellur S, et al. VALIGA study of the ERA-EDTA Immunonephrology Working Group: validation of the Oxford classifification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–836.
   PubMed Web of Science ®Google Scholar
• Hou JH, Le WB, Chen N, et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: a Randomized Controlled Trial. Am J Kidney Dis. 2017;69(6):788–795. doi:10.1053/j.ajkd.2016.11.027
   PubMed Web of Science ®Google Scholar
• Gutiérrez E, Zamora I, Ballarín JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23(10):1753–1760. doi:10.1681/ASN.2012010063
   PubMed Web of Science ®Google Scholar
• Edström Halling S, Söderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant. 2012;27(2):715–722. doi:10.1093/ndt/gfr339
   PubMed Web of Science ®Google Scholar
• Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 2016;29(3):367‐375. doi:10.1007/s40620-015-0227-8
   PubMed Web of Science ®Google Scholar